Send to

Choose Destination
See comment in PubMed Commons below
Oncoimmunology. 2013 Apr 1;2(4):e23440.

Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines.

Author information

  • 1Institute for Cellular Therapeutics; Department of Microbiology and Immunology; University of Louisville; Louisville, KY USA ; James Graham Brown Cancer Center; University of Louisville; Louisville, KY USA.


Tumor-associated antigen (TAA) subunit-based vaccines constitute promising tools for the anticancer immunotherapy. Given the weak antigenic nature of most TAAs, however, the efficacy of TAA-based vaccines requires adjuvants exerting potent immunostimulatory functions. Co-stimulatory members of the tumor necrosis factor ligand (TNFL) family may be used in this sense due to their pleiotropic and robust effects on cells of innate, adaptive and regulatory immune responses.


CD137; SA-4-1BBL; anticancer immunity; cancer vaccines; lung cancer; survivin

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Write to the Help Desk